Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

21. Irritable bowel syndrome: Bulk-forming laxatives

Irritable bowel syndrome: Bulk-forming laxatives Bulk-forming laxatives | Prescribing information | Irritable bowel syndrome | CKS | NICE Search CKS… Menu Bulk-forming laxatives Irritable bowel syndrome: Bulk-forming laxatives Last revised in October 2017 Bulk-forming laxatives Bulk-forming laxatives (containing soluble fibre) act by retaining fluid within the stool and increasing faecal mass, stimulating peristalsis; also have stool-softening properties. Ispaghula husk (also known as psyllium (...) before bed. Adequate fluid intake is important, to prevent intestinal obstruction. Tablets swell in the mouth on contact with water. Typically takes 2–3 days to take effect. [ ; ; ] Contraindications and cautions Do not prescribe laxatives if there is suspected: Intestinal obstruction or perforation. Paralytic ileus. Colonic atony or faecal impaction (bulk-forming laxatives). Crohn's disease or ulcerative colitis. Toxic megacolon. Prescribe laxatives with caution if there is: Fluid and electrolyte

2019 NICE Clinical Knowledge Summaries

22. Irritable bowel syndrome: Antispasmodic drugs

Irritable bowel syndrome: Antispasmodic drugs Antispasmodic drugs | Prescribing information | Irritable bowel syndrome | CKS | NICE Search CKS… Menu Antispasmodic drugs Irritable bowel syndrome: Antispasmodic drugs Last revised in October 2017 Antispasmodic drugs Antispasmodic drugs may be used as required for abdominal pain or spasm in irritable bowel syndrome (IBS). Drug options include: Direct-acting smooth muscle relaxants such as mebeverine hydrochloride (immediate-release or modified (...) for up to 2–3 months if needed, dose to be taken before meals, swallowed whole with water. [ ] Contraindications and cautions Do not prescribe direct-acting smooth muscle relaxants (such as mebeverine hydrochloride or alverine citrate) to people with: Intestinal obstruction. Paralytic ileus. Prescribe peppermint oil with caution to people with: Sensitivity to menthol. [ ] Adverse effects Possible adverse effects of: Alverine citrate include dizziness, dyspnoea, headache, hepatitis, jaundice (resolves

2019 NICE Clinical Knowledge Summaries

23. Irritable bowel syndrome: Antidepressant drugs

Irritable bowel syndrome: Antidepressant drugs Antidepressant drugs | Prescribing information | Irritable bowel syndrome | CKS | NICE Search CKS… Menu Antidepressant drugs Irritable bowel syndrome: Antidepressant drugs Last revised in October 2017 Antidepressant drugs Tricyclic antidepressants (TCAs) such as amitriptyline, may be used for the management of pain associated with irritable bowel syndrome (off-label indication). The National Institute for Health and Care Excellence (NICE (...) therapy. Diabetes mellitus. Epilepsy — stop treatment if seizures develop. History of bleeding disorders, especially gastrointestinal bleeding. Susceptibility to angle-closure glaucoma. Susceptibility to QT interval prolongation (citalopram only). [ ] Adverse effects Possible adverse effects of amitriptyline include: Abdominal pain, fatigue, hypertension, mydriasis, oedema, palpitations, restlessness, stomatitis. Dysarthria, extrapyramidal symptoms, tremor, paralytic ileus. Possible adverse effects

2019 NICE Clinical Knowledge Summaries

24. Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up Full Text available with Trip Pro

Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up There is a need for safe and effective IBS treatments that provide immediate and sustained improvement of IBS symptoms, particularly among more severe patients. The aim was to assess long-term clinical response of cognitive behavioral therapy (CBT) with reference to IBS education.A total of 436 Rome III-diagnosed IBS patients (80% F, M age = 41 years) were randomized to: 4 (...) with negligible decay. For MC-CBT and S-CBT, 39 and 33% of respondents maintained treatment response at every follow-up assessment. The corresponding percent for EDU was 19%, which was significantly lower (p < 0.05) than for the CBT groups. On the IBS-SSS, therapeutic gains also showed a pattern of maintenance with trends towards increased efficacy over time in all conditions, with the mean unit reductions between baseline and follows-up being approximately -76 at immediate and approximately -94 at 12 months

2018 EvidenceUpdates

25. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome (Abstract)

Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome More effective treatments are needed for patients with postinfectious, diarrhoea-predominant, irritable bowel syndrome (IBS-D). Accordingly, we conducted a randomised, double-blind, placebo-controlled, 8-week-long trial to assess the efficacy and safety of oral glutamine therapy in patients who developed IBS-D with increased intestinal permeability following an enteric (...) infection.Eligible adults were randomised to glutamine (5 g/t.i.d.) or placebo for 8 weeks. The primary end point was a reduction of ≥50 points on the Irritable Bowel Syndrome Severity Scoring System (IBS-SS). Secondary endpoints included: raw IBS-SS scores, changes in daily bowel movement frequency, stool form (Bristol Stool Scale) and intestinal permeability.Fifty-four glutamine and 52 placebo subjects completed the 8-week study. The primary endpoint occurred in 43 (79.6%) in the glutamine group and 3 (5.8

2018 EvidenceUpdates

26. Irritable bowel syndrome

on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Top results for irritable bowel syndrome 1. Probiotics for irritable bowel syndrome 2017 2. Irritable bowel syndrome Irritable bowel syndrome - NICE CKS Clinical Knowledge Summaries Share Irritable bowel syndrome - Summary Irritable bowel syndrome ( IBS ) is a chronic, relapsing, and often lifelong disorder of gastrointestinal function (...) of irritable bowel syndrome Poynard T, Regimbeau C, Benhamou Y Authors' objectives To assess the efficacy and tolerance of smooth muscle relaxants in the treatment of irritable bowel syndrome ( IBS ). Searching A search of MEDLINE and a manual search were combined (...) . The keywords used were 'colonic disease ', 'functional', irritable bowel syndrome ' and 'randomised trial'. Additional studies were obtained by examining general reviews, references from published RCTs, and Current Contents

2018 Trip Latest and Greatest

27. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study Full Text available with Trip Pro

Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study IBS is associated with an intestinal dysbiosis and faecal microbiota transplantation (FMT) has been hypothesised to have a positive effect in patients with IBS. We performed a randomised, double-blind placebo-controlled trial to investigate if FMT resulted in an altered gut microbiota and improvement in clinical outcome in patients

2018 EvidenceUpdates

28. Irritable bowel syndrome

Irritable bowel syndrome Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) of known issues . Also read , explaining issues with the system. NOTE : Chrome is the best browser to use! To get started, type a condition/disease into the search box above. Here are some examples to get you started: Building Evidence Map X Axis Alphabetically Risk of bias No. Articles Sample Size Risk of bias any low Minimum sample size Apply Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK.

2018 Trip Evidence Maps

29. Naturopathic approaches to irritable bowel syndrome: protocol for a prospective observational study in academic teaching clinics Full Text available with Trip Pro

Naturopathic approaches to irritable bowel syndrome: protocol for a prospective observational study in academic teaching clinics Irritable bowel syndrome (IBS) is a common functional bowel disorder with a worldwide prevalence estimated between 10% and 20%. It has a significant impact on quality of life and societal expense. While there are pharmaceutical options available, few can be reliably recommended. Many IBS sufferers turn to complementary and alternative medicine including naturopathy

2018 Integrative medicine research

30. Eluxadoline (Viberzi) - irritable bowel syndrome with diarrhea (IBS-D)

Eluxadoline (Viberzi) - irritable bowel syndrome with diarrhea (IBS-D) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved

2018 Health Canada - Drug and Health Product Register

31. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials (Abstract)

Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials Two identical, phase 3, randomized, double-blind, placebo-controlled trials evaluated the efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C).Adults meeting Rome III criteria for IBS-C were randomized (1:1:1) to placebo or plecanatide (3 or 6 mg) for 12 weeks. The primary efficacy end (...) point was the percentage of overall responders (patients reporting ≥30% reduction from baseline in worst abdominal pain plus an increase of ≥1 complete spontaneous bowel movement (CSBM)/week from baseline in the same week for ≥6 of 12 treatment weeks). Safety was assessed by adverse events (AEs).Overall, 2189 individuals were randomized across the two studies and 1879 completed the studies. Demographic and baseline characteristics were similar across treatment groups and between studies

2018 EvidenceUpdates

32. Irritable bowel syndrome

be individualised and is dependent on the patient's predominant symptoms. Definition Irritable bowel syndrome (IBS) is a chronic condition characterised by abdominal pain associated with bowel dysfunction. The pain is often relieved by defecation and is sometimes accompanied by abdominal bloating. There are no structural abnormalities to explain the pain. IBS occurs in about 15% of the adult population. The aetiology is probably multi-factorial and evidence suggests motility, inflammatory, genetic, immune (...) , psychological, and dietary components. Drossman DA, Camilleri M, Mayes FA. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002 Dec;123(6):2108-31. http://www.ncbi.nlm.nih.gov/pubmed/12454866?tool=bestpractice.com History and exam presence of risk factors abdominal discomfort alteration of bowel habits associated with pain abdominal bloating or distension normal examination of abdomen passage of mucus with stool physical and sexual abuse age <50 years female sex previous enteric

2018 BMJ Best Practice

33. Viberzi - eluxadoline - Irritable bowel syndrome with diarrhea

and drug plans August 24, 2018 CDEC Final Recommendation posted August 29, 2018 Final CDR review report(s) and patient input posted September 18, 2018 Tags digestive system, gastrointestinal tract, diarrhea, irritable bowel syndrome, irritable bowel; Diarrhea Files Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter: (...) Viberzi - eluxadoline - Irritable bowel syndrome with diarrhea eluxadoline | CADTH.ca Find the information you need eluxadoline eluxadoline Last Updated: September 18, 2018 Result type: Reports Project Number: SR0560-000 Product Line: Generic Name: eluxadoline Brand Name: Viberzi Manufacturer: Allergan Pharma Co. Indications: Irritable bowel syndrome with diarrhea Manufacturer Requested Reimbursement Criteria 1 : As per the Health Canada-approved indication (for the tretment of irritable bowel

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

34. Irritable bowel syndrome

Irritable bowel syndrome Irritable bowel syndrome | Topics A to Z | CKS | NICE Search CKS… Menu Irritable bowel syndrome Irritable bowel syndrome Last revised in October 2017 Irritable bowel syndrome (IBS) is a chronic, relapsing, and often lifelong disorder of the lower gastrointestinal tract, with no structural cause Diagnosis Management Prescribing information Background information Irritable bowel syndrome: Summary Irritable bowel syndrome (IBS) is a chronic, relapsing, and often lifelong (...) disorder of the lower gastrointestinal tract, with no discernible structural or biochemical cause. Typical clinical features are abdominal pain: Associated with a change in stool form and/or frequency. Which may be related to defaecation, and there may be associated bloating. The exact underlying cause of IBS is unknown, but is likely to be multifactorial. The global prevalence of IBS in the general population is estimated to be 5–20%. The symptoms of IBS may fluctuate over years. A diagnosis of IBS

2018 NICE Clinical Knowledge Summaries

35. Self-Perception of Iranian Patients during their life with Irritable Bowel Syndrome: A Qualitative Study Full Text available with Trip Pro

Self-Perception of Iranian Patients during their life with Irritable Bowel Syndrome: A Qualitative Study Irritable bowel syndrome (IBS), as a chronic digestive disorder, impacts extensively on the quality of life, emotional well-being and self-identity. Chronic illness disrupts taken-for-granted notions about self. No qualitative study was found regarding patients' experience of life with irritable bowel syndrome (IBS) in Iran.To explore the self-perception of lived experience of IBS patients.A

2017 Electronic physician

36. A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial Full Text available with Trip Pro

A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial Dietary restriction of fermentable carbohydrates (a low FODMAP diet) has been reported to reduce symptoms in some patients with irritable bowel syndrome (IBS). We performed a randomized, placebo-controlled study to determine its effects on symptoms and the fecal microbiota in patients with IBS.We performed a 2×2 factorial trial of 104 (...) number of staple and non-staple foods as the low FODMAP diet; the diets had similar degrees of difficulty to follow. Dietary counselling was given to patients in all groups and data on foods eaten and compliance were collected. The incidence and severity of 15 gastrointestinal symptoms and overall symptoms were measured daily for 7 days before the study period; along with stool frequency and consistency. At baseline, global and individual symptoms were measured, along with generic and disease

2017 EvidenceUpdates

37. Eluxadoline for treating irritable bowel syndrome with diarrhoea

, having considered evidence on the nature of irritable bowel syndrome with diarrhoea (IBS-D) and the value placed on the benefits of eluxadoline by people with the condition, those who represent them, and clinical experts. It also took into account the effective use of NHS resources. Nature of the condition 4.2 The committee was aware of the experiences of people with IBS-D. It heard that IBS-D is diagnosed after physicians rule out other conditions, including inflammatory bowel disease, colorectal (...) it appropriate to stop. Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 242 2 The technology The technology Description of Description of the technology the technology Eluxadoline (Truberzi, Allergan) is an opioid receptor agonist and delta-opioid receptor antagonist that binds to opioid receptors in the digestive system and slows down the movement

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

38. Effects of a Low FODMAP Diet and Specific Carbohydrate Diet on Symptoms and Nutritional Adequacy of Patients with Irritable Bowel Syndrome: Preliminary Results of a Single-blinded Randomized Trial Full Text available with Trip Pro

Effects of a Low FODMAP Diet and Specific Carbohydrate Diet on Symptoms and Nutritional Adequacy of Patients with Irritable Bowel Syndrome: Preliminary Results of a Single-blinded Randomized Trial IBS is the most common functional disease of the low gastrointestinal tract. Recently, the interest towards a diet approach has increased, for example, a diet with low content of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs). The aim of the present study

2017 Journal of translational internal medicine Controlled trial quality: uncertain

39. Irritable Bowel Syndrome. (Abstract)

Irritable Bowel Syndrome. This issue provides a clinical overview of irritable bowel syndrome, focusing on diagnosis, treatment, and practice improvement. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic in collaboration with the ACP's Medical Education and Publishing divisions

2017 Annals of Internal Medicine

40. Home-Based Hypnotherapy Self-exercises vs Individual Hypnotherapy With a Therapist for Treatment of Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, or Functional Abdominal Pain Syndrome: A Randomized Clinical Trial (Abstract)

Home-Based Hypnotherapy Self-exercises vs Individual Hypnotherapy With a Therapist for Treatment of Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, or Functional Abdominal Pain Syndrome: A Randomized Clinical Trial Individual gut-directed hypnotherapy (HT) is effective in pediatric irritable bowel syndrome (IBS) and functional abdominal pain or functional abdominal pain syndrome (FAP[S]). It is, however, unavailable to many children.To compare the effectiveness of HT by means

2017 EvidenceUpdates